Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q1 FY27 results · Apr–Jun 2026
Jubilant Pharmova reported revenue from operations of ₹2,229.40 crore (up 17.3% from Q1 FY26) and net profit of ₹56.40 crore (down 45.0% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,229.40 | 1,900.70 | +17.3% | 2,290.00 | −2.6% |
| Other income | 19.90 | 12.00 | +65.8% | 23.70 | −16.0% |
| Total income | 2,249.30 | 1,912.70 | +17.6% | 2,313.70 | −2.8% |
| Profit before tax | 86.40 | 154.50 | −44.1% | 176.00 | −50.9% |
| Net profit for the period | 56.40 | 102.50 | −45.0% | 119.30 | −52.7% |
| Attributable to shareholders of the company | 56.50 | 102.90 | −45.1% | 119.40 | −52.7% |
| EPS, basic (₹) | 3.57 | 6.49 | −45.0% | 7.55 | −52.7% |
| Net margin (%) | 2.5 | 5.4 | 5.2 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 67.10 | 59.50 | +12.8% | 70.30 | −4.6% |
| Other income | 0.10 | 0.70 | −85.7% | 0.50 | −80.0% |
| Total income | 67.20 | 60.20 | +11.6% | 70.80 | −5.1% |
| Profit before tax | 9.80 | 6.50 | +50.8% | 4.10 | +139.0% |
| Net profit for the period | 7.30 | 5.80 | +25.9% | 57.20 | −87.2% |
| EPS, basic (₹) | 0.46 | 0.36 | +27.8% | 3.59 | −87.2% |
| Net margin (%) | 10.9 | 9.7 | 81.4 |
Consolidated
- Filed with BSE
- 10 Aug 2026, 19:29 IST
- Board meeting
- 10 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2026, 19:29 IST
- Board meeting
- 10 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE